Annals of hematology · 2019
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caocci Giovanni, Mulas Olga, Abruzzese Elisabetta, Iurlo Alessandra, Annunziata Mario, Orlandi Ester Maria, Galimberti Sara, Binotto Gianni, Sgherza Nicola, Luciano Luigia, Martino Bruno, Russo Rossi Antonella, Bonifacio Massimiliano, Fozza Claudio, Trawinska Malgorzata Monika, Cattaneo Daniele, Elena Chiara, Baratè Claudia, De Gregorio Fiorenza, Molica Matteo, La Nasa Giorgio, Foà Robin, Breccia Massimo
Аннотация
There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high-very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAngina PectorisAniline CompoundsAntineoplastic AgentsBrain IschemiaDasatinibDisease SusceptibilityDrug Administration ScheduleFemaleHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedMyocardial InfarctionNitrilesPeripheral Vascular DiseasesProtein Kinase InhibitorsPyrimidinesQuinolinesRetrospective Studies